Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Beremagene Geperpavec · Vyjuvek, KB-103

Gene therapy · Gene replacement · developed by Krystal Biotech

Approved FDA, May 2023
KRYS Developer
2 Registered trials

What is Beremagene Geperpavec?

Beremagene geperpavec is a topical gene therapy based on a non-integrating, replication-incompetent herpes simplex virus type 1 vector that carries the human COL7A1 gene. After application to wounds, it transduces keratinocytes and fibroblasts, which then produce collagen VII to form anchoring fibrils. It is studied in dystrophic epidermolysis bullosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vyjuvek, KB-103
Drug type
Gene therapy
Mechanism
Gene replacement
Pathways
COL7 production and anchoring fibril formation
Therapy area
Dermatology
Developer
Krystal Biotech, Inc. (KRYS)
FDA status
Approved as Vyjuvek (May 19, 2023), BLA125774 · FDA label
UNII
AQN7K24KQU

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 29, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04917874 Phase 3 Dystrophic Epidermolysis Bullosa Completed KRYS
NCT04491604 Phase 3 Dystrophic Epidermolysis Bullosa Completed KRYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DEB - Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaDystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa

More from Krystal Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.

Follow KRYS, the company behind Beremagene Geperpavec

See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KRYS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.